



Emerging Treatment Strategies for Multiple Myeloma

Guest Editor:

Dr. Jo Caers

Department of Hematology, CHU
de Liège, University of Liege,
Liege, Belgium.

Deadline for manuscript
submissions:

closed (30 November 2021)

Message from the Guest Editor

The outcome of multiple myeloma has improved in recent decades. Proteasome inhibitors, immune-modulators and monoclonal antibodies have shown impressive antimyeloma activity and are currently incorporated in clinical regimens. New immunotherapeutic strategies such as CAR-T cells and bispecific antibodies are currently explored and target new antigens such as BCMA, SLAMF7 or GPRC5D. In addition, new signaling pathways (BCL2 family proteins, MYC, BRD4) are being targeted by small molecule inhibitors or PROTACs, and the latter are being evaluated in multiple myeloma because of its incurable nature.

For this Special Issue, we are inviting you to submit papers on new immunotherapeutic strategies or targets, new inhibitors or signaling pathways that are in preclinical or clinical evaluation

Dr. Jo Caers
Guest Editor





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI